• Product name
    Anti-VEGFA antibody [16F1]
    See all VEGFA primary antibodies
  • Description
    Mouse monoclonal [16F1] to VEGFA
  • Host species
  • Tested applications
    Suitable for: WB, Sandwich ELISA, IHC-Pmore details
  • Species reactivity
    Reacts with: Human, Recombinant fragment
  • Immunogen

    Recombinant full length Human VEGFA expressed in E-coli (P15692)

  • Positive control
    • Human VEGFA recombinant protein; Human VEGFA transfected 293T cells.



Our Abpromise guarantee covers the use of ab155944 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml.
Sandwich ELISA Use a concentration of 1 µg/ml.

Typical dilutions for sandwich ELISA include 1µg/ml for coating and 0.125-0.5µg/ml for detection.

IHC-P Use at an assay dependent concentration. PubMed: 24651519


  • Function
    Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
  • Tissue specificity
    Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
  • Involvement in disease
    Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
  • Sequence similarities
    Belongs to the PDGF/VEGF growth factor family.
  • Cellular localization
    Secreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
  • Information by UniProt
  • Database links
  • Alternative names
    • Folliculostellate cell-derived growth factor antibody
    • Glioma-derived endothelial cell mitogen antibody
    • MGC70609 antibody
    • MVCD1 antibody
    • Vascular endothelial growth factor A antibody
    • vascular endothelial growth factor A121 antibody
    • vascular endothelial growth factor A165 antibody
    • vascular endothelial growth factor antibody
    • Vascular permeability factor antibody
    • VEGF A antibody
    • Vegf antibody
    • VEGF-A antibody
    • VEGF120 antibody
    • Vegfa antibody
    • VEGFA_HUMAN antibody
    • VPF antibody
    see all


  • All lanes : Anti-VEGFA antibody [16F1] (ab155944) at 1 µg/ml

    Lane 1 : VEGFA transfected 293T cell culture supernatant
    Lane 2 : Recombinant VEGFA protein

    Lysates/proteins at 0.5 µg per lane.

    4-12% HCl
  • Sandwich ELISA analysis of Human VEGFA protein, labeling Human VEGFA at 2000,1000, 500, 250, 125,62.5, 31.25 and 0pg/ml with ab155944 at 1,3,4,5,7 and 9 µg/ml.


This product has been referenced in:
  • Yu X  et al. AEG-1 Contributes to Metastasis in Hypoxia-Related Ovarian Cancer by Modulating the HIF-1alpha/NF-kappaB/VEGF Pathway. Biomed Res Int 2018:3145689 (2018). Read more (PubMed: 29770329) »
  • Zhao X  et al. MicroRNA-205 is downregulated in hepatocellular carcinoma and inhibits cell growth and metastasis via directly targeting vascular endothelial growth factor A. Oncol Lett 16:2207-2214 (2018). Read more (PubMed: 30008920) »
See all 6 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab155944.
Please use the links above to contact us or submit feedback about this product.


Sign up